31 Jan 2022 , 09:30 AM
Granules India Limited announced on Monday that wholly-owned subsidiary Granules Pharmaceuticals, Inc. (GPI), located in Chantilly, Virginia, USA had undergone a Preapproval Inspection (PAI) by the US Food and Drug Administration (USFDA) from January 24-28, 2022.
The audit is a PAI for two of its product applications filed from this facility. The USFDA issued three minor observations during the audit conducted at the facility.
“We are glad to have completed yet another audit with minor observations that we will respond to within the stipulated time period,” Priyanka Chigurupati, Executive Director, GPI, said.
At around 9.30 am, Granules India Ltd was trading at Rs306.45 per piece up by Rs5.95 or 1.98% from its previous closing of Rs300.50 per piece on the BSE.
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.